Abstract
Background. The first RSV vaccines for adults 60 years and older were approved prior to the 2023-2024 respiratory virus season. This study used data from adults 60 years and older, enrolled into the Community Vaccine Effectiveness (CoVE) cohort study, in Michigan, U.S.A, to evaluate RSV vaccine effectiveness (VE) and antibody correlates of protection. Methods. A Cox proportional hazards model was used to compare incidence of symptomatic / all RSV infections in those vaccinated versus unvaccinated. RSV-specific (preF) binding antibodies were measured in serum specimens and assessed longitudinally. A correlates of protection analysis was conducted using logistic regression. Findings. Of the 281 participants (n=117 vaccinated) enrolled (August 1, 2023, to March 1, 2024), 14 tested positive for RSV. Adjusted RSV VE against any RSV infection was 50.8% (95%CI: -79.1% to 86.5%), and 59.8% (95%CI: -105.2% to 92.1%) against symptomatic RSV. There were 61.2 (95%CI: 16.9, 163.2) RSV infections per 1,000 person-years among vaccinated participants compared to 165.8 infections (95%CI: 88.0, 287.0) per 1,000 person-years among those unvaccinated. A 31% decrease in odds (OR: 0.69, 95% CI: 0.44 to 1.07) of RSV infection per 2-fold increase in antibody concentration was observed. Interpretation. RSV infection risk was lower among those with higher antibody titers. RSV incidence was lowest among vaccinated adults, but not significantly. Continued monitoring of reduction of RSV infection in years following vaccination is warranted. Funding. National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention (75D30122C13149) and National Institute of Allergy and Infectious Diseases (75N93021C00015). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funding from the National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention (75D30122C13149), and the National Institute of Allergy and Infectious Diseases and the National Institutes of Health (75N93021C00015).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Michigan Medical School Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos